Medical Advocates
Maraviroc (Selzentry)
 
Conference Citations

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
XIX IAC
 6th IAS Conference
XVIII IAC
5th IAS Conference
Ninth Int Congress on Drug Therapy in HIV Infection
 Conference Archives

  
Maraviroc Main Page Main New/Newsworthy  Home Page      
Last Update:  January 26, 2015 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
 
  • A WEEK-IN-REVIEW FEATURED REPORT
    POSTER
     Safety and efficacy of maraviroc-raltegravir combination following 6 months induction with maraviroc-raltegravir-tenofovir-emtricitabine in naïve HIV-1-infected patients with CCR5 virus: interim analysis of the No Nuc No Boost study
    L. Cotte1, J. Durant, C. Brochier, P. André
    Poster    Abstract
  • Safety and efficacy of maraviroc in CCR5-tropic HIV-1-infected children aged 2 to < 18 years
    C. Giaquinto, L. Keet, C. Fortuny, et al
    Abstract
  • Maraviroc (MVC) intensification can activate NFkB through CCR5 and the expression of its target genes in resting CD4+ T cells in suppressed HIV-1-infected patients
    N. Madrid-Elena, B. Hernandez-Novoa, L. Garcia-Bermejo, S. Moreno
    Abstract
  • Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2 to < 18 years
    M. Vourvahis, L. McFadyen, T. Checchio, et al
    Abstract
  • Modelling HIV PrEP in humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir, tenofovir and maraviroc
    R. Akkina, M. Veselinovic C.P. Ne et al
    Abstract
     

XIX International AIDS Conference
     
  • Horizontal transmission of HIV-1 exhibiting resistance to four antiretroviral drug classes, including integrase inhibitors
    C. Walworth, D. Ward, L. Napolitano, et a    l
    Abstract
  • Sustained release tenofovir and maraviroc from intravaginal ring in sheep
    T.J. Smith
6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • POSTER
    Clinical validation of standard population-based and deep sequencing genotypic tropism tests using virological
    response to a short-term monotherapy maraviroc exposure
    A. Gonzalez-Serna, R.A. McGovern, R. Harrigan, et al
    P    oster     Abstract
  • POSTER
    Natural resistance to Maraviroc in HIV-infected patients: study by genetic forms and co-receptors usage
    Y. Vega, A. Fernandez-García, E. Delgado, et al
     Poster     Abstract
  • POSTER
    Immunological efficacy of maraviroc (MVC) as intensification strategy in HIV-infected patients (pts) failing CD4
    recovery on virologically-suppressive HAART
    S. Rusconi, E. Colella, F. Adorni, et al
     Poster    Abstract
  • POSTER
    Study of the immunomodulant effect of darunavir and maraviroc on apoptosis of PBMC
    I. Sauzullo, F. Mengoni, A. Ermocida, et al
     Poster     Abstract
  • POSTER
    Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for naïve patients: preliminary 48-weeks
    results
    S. Nozza, L. Galli, A. Antinori, M.     et al
    Poster     Abstract
  • POSTER
    Persistence of antiretroviral regimens including raltegravir, maraviroc, darunavir and/or etravirine in clinical practice
    I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
    Poster     Abstract
  • POSTER
    No maraviroc (MVC) concentration exposure-response relationship identified for 48-week efficacy (< 50 copies/mL) in treatment-experienced patients in the MOTIVATE studies when undetectable MVC concentrations were accounted for separately from MVC concentrations
    L. McFadyen P. Jacqmin, B. Weatherley,  et a    l
     Poster     Abstract
  • POSTER
    Maraviroc (MVC) pharmacokinetics (PK) in CCR5-tropic HIV-1-infected children aged 2-< 18 years: preliminary results from study A4001031
    M. Vourvahis, L. McFadyen, B. Duncan, et al
     Poster     Abstract
  • POSTER
    Safety and efficacy of maraviroc (MVC) in CCR5-tropic HIV-1-infected children aged 2 to < 18 years
    C. Giaquinto, J. Fourie, I. Mitha, et al
     Poster     Abstract
  • POSTER
    Efficacy of maraviroc (MVC) administered once daily (QD) or twice daily (BID) with boosted protease inhibitors (bPIs) to treatment-experienced patients
    S. Taylor, J. Arribas, C.-F. Perno,  et al
     Poster     Abstract
  • 48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with
    ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in
    |treatment-naïve (TN) patients infected with CCR5-tropic H
     S. Portsmouth, C. Craig, A. Mills,     et al
    Abstract
  • Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients
     P. Nasta, F. Gatti, F. Borghi,  et al 
    Abstract
  • Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly sensitive to anti-gp120
    neutralizing antibodies and autologous plasma IgG under high concentrations of the CCR5 inhibitor
    K. Yoshimura, S. Harada, A. Hamaji, S. Matsushita
    Abstract
  • HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism
    of gp120-CCR5 engagement that attenuates macrophage tropism
     M. Roche, M.R. Jakobsen, J. Sterjovski, et al
    Abstract
  • Next generation deep sequencing to evaluate viral tropism in HIV-1 patients exposed to maraviroc add-on therapy
    for eight days
    R.A. McGovern, A.F.Y. Poon,     et al
    Abstract
  • Plasma viral load underestimates the antiviral efficacy of maraviroc
    V. Kramer, S. Schader, M. Oliviera,  et al
    Abstract
  • Effect of maraviroc treatment in a patient with a dual-tropic viral population
    L. Mainetti, A. Galli, A. Pignataro, et al
    Abstract
  • Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a
    novel NRTI-sparing regimen in naïve patients
    S. Bonora, S. Nozza, D. Gonzalez de Requena, et al
    Abstract
  • Prevalence of X4-tropic viruses in HIV-1-infected patients according to CD4 counts, viral load and antiretroviral
    exposure
    E. Seclén, V. Soriano, M.M. Gonzalez, et al
    Abstract
  • Human primary macrophages and lymphocytes are differently infected by HIV-1 dual/mixed variants: study of
    susceptibility to CCR5- and CXCR4-inhibitors
    E. Balestra, M. Surdo, P. Saccomandi, et al
    Abstract
  • Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly sensitive to anti-gp120 neutralizing antibodies and autologous plasma IgG under high concentrations of the CCR5 inhibitor
    K. Yoshimura, S. Harada, A. Hamaji,  et al
    Abstract
XVIII International AIDS Conference
 
  • POSTER
    Maraviroc in treatment-experienced patients
    G. Sterrantino, M. Trotta, P.G. Rogasi, et al
    PDF Poster         Abstract
  • POSTER
         Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in
    clinical practice
    I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
    PDF Poster        Abstract
  • POSTER
    Low risk of malignancy with maraviroc in treatment-experienced (TE) and treatment-naïve (TN)
    patients across the maraviroc clinical development program
    S. Walmsley, R. Campo, J. Goodrich, et al
    PDF Poster         Abstract
  • POSTER
         Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in
    clinical practice
    I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
    PDF Poster        Abstract
  • POSTER
    Efficacy and safety of MVC in treatment-experienced over-sixty patients
    G. Sterrantino, B. Borchi, M. Trotta, et al
    PDF Poster         Abstract
  • POSTER
    Virologic outcome by V3 loop genotypic population sequencing and 454 ‘deep sequencing’ in clade B
    and non-B virus in MERIT at 48 and 96 weeks
    S. Portsmouth1, D. Chapman1, M. Lewis, et al
    PDF Poster         Abstract
  • POSTER
    Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting r
    esponse in a treatment-experienced (TE) population
    P. Biswas, D. Chapman, X. Zhong, et al
    PDF Poster         Abstract
  • POSTER
    Effect of 24 weeks intensificaction with a CCR5-antagonist on the decay of the HIV-1 latent reservoir
    L. Díaz, C. Gutierrez, C. Page, et al
    PDF Poster        Abstract
  • POSTER
    Effect of a CCR5 antagonist in immune activation in highly suppressed HIV-1 infected patients
    A. Vallejo1, L. Diaz, M. Abad, et al
    PDF Poster         Abstract
  • Maraviroc containing regimen suppress cerebrospinal fluid HIV replication in HIV-1 infected patients
    with neurological symptoms
    G. Melica, A. Canestri, G. Peytavin, et al
    Abstract
  • Clinical outcome of HIV tropism testing and Maraviroc regimens – 48 weeks follow-up
    H. Knechten, F. Wiesmann, E. Wolf, et al
    Abstract
  • Hard rescue: prospective study of effectiveness and safety of new drugs (Darunavir-DRV,
    Etravirina-ETR, Raltegravir-RTG andMaraviroc-MVC) in the last four years (2006-2009)
    H. Azkune Galparsoro,.A. Iribarren Loyarte, M.J. Aramburu Bengoechea, et al
    Abstract
  • In vivo synergistic activity of maraviroc and raltegravir in the reduction of HIV proviral burden in
    circulating reservoirs
    C. Tommasi, E. Nicastri, I. Abbate, et al
    Abstract
  • mDAPTA, a potent CCR5 receptor blocker, prevents viral recovery from CD8-depleted patient PBMCs
    with VL< 50 background
    L. Agrawal, O. Ducoudret, N. Baichoo, et al
    Abstract
  • Detection of CXCR4-using variants in circulating and proviral HIV quasispecies from patients treated
    with CCR5 antagonist by ultra-deep pyrosequencing
    I. Abbate, G. Rozera, C. Tommasi, et al
    Abstract
  • Maternal-fetal pharmacokinetics of a single intrapartum dose of maraviroc in rhesus macaques
    M. Winters1,, K. Van Rompay, A. Kashuba,,et al
    Abstract
  • Safety and immunovirological activity of once daily maraviroc (MVC) in combination with
    ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200mg/tenofovir 300mg QD
    (TDF/FTC) + ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study A4001078):
    A week 24 planned interim analysis
    A. Mills, D. Mildvan, D. Podzamczer, et al
    Abstract
5th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results
    J. Heera, P. Ive, M. Botes, et al
     Abstract
  • Incidence of malignancies in treatment-experienced (TE) patients in the MOTIVATE studies
    of maraviroc (MVC) + optimized background therapy (OBT): 96 week follow-up
    A. Ayoub, S. Walmsley, R. Campo,  et al
     Abstract
  • Concurrent use of statins does not influence efficacy of maraviroc in MOTIVATE studies
    G. Moyle, N. Rajicic, H. Valdez, et al
     Abstract
  • Virologic suppression on maraviroc in treatment-naïve patients with R5 HIV-1 is similar
    to efavirenz at high baseline viral load, and maraviroc discontinuations for adverse events
    are less likely to show drug resistance: 48-week results from the MERI
    M. Nelson, A. Lazzarin, G. Di Perri, et al
     Abstract
  • Anti-HIV activity of the candidate microbicide maraviroc, a CCR5 receptor antagonist
    P.S. Fletcher, C. Herrera, N. Armanasco, et al
     Abstract
Ninth International Congress on Drug Therapy in HIV Infection
 

Maraviroc Main Page Main New/Newsworthy  Home Page      

Maraviroc (Selzentry) Conference Citations